Tampa, FL, United States of America

Shari Pilon-Thomas

This inventor holds 7 USPTO granted patents and 7 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignees: H. Lee Moffitt Cancer Center and Research Institute, Inc., University of South Florida, Board Nf Regents the Inivercitvof Texas Cvctom. Active years: 2013-2026.

USPTO Granted Patents = 7 

% Patents Active = 100.0

 

 

Average Co-Inventor Count = 4.7

ph-index = 3

Forward Citations = 14(Granted Patents)


Company Filing History:


Years Active: 2013-2026

Loading Chart...
Loading Chart...
Loading Chart...
7 patents (USPTO):Explore Patents

Title: Shari Pilon-Thomas: Innovator in Cancer Therapy

Introduction

Shari Pilon-Thomas is a prominent inventor based in Tampa, FL, known for her significant contributions to cancer therapy. With a total of six patents to her name, she has made remarkable strides in the field of adoptive cell therapy.

Latest Patents

Her latest patents focus on tumor-infiltrating lymphocytes for adoptive cell therapy. These patents disclose compositions and methods for the ex vivo expansion of tumor-infiltrating lymphocytes, which are crucial for use in adoptive cell therapy (ACT). Additionally, they include methods for identifying agents that facilitate this expansion and outline innovative approaches for treating cancer using these expanded lymphocytes.

Career Highlights

Shari has worked at esteemed institutions such as the H. Lee Moffitt Cancer Center and Research Institute and the University of South Florida. Her work has been instrumental in advancing the understanding and application of cancer treatments.

Collaborations

Some of her notable coworkers include Amod A Sarnaik and Hao Liu, who have collaborated with her on various research projects.

Conclusion

Shari Pilon-Thomas continues to be a leading figure in cancer research, with her innovative patents paving the way for new therapeutic approaches. Her dedication to improving cancer treatment through scientific innovation is commendable.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…